The Changing Landscape of HCV Treatment: Assessing All the Options

   

HCV Landscape 2016 Web Banner_v2


HCVOnline_Launch 


About the Program:

Program Overview:

The hepatitis C virus (HCV) afflicts millions of people in the United States. The past several years have witnessed great improvements in our ability to treat HCV infection.  Rapid developments in the field of HCV patient management enable clinicians to have an increasing number of treatment options to treat a variety of different patient types, including those with cirrhosis, various HCV genotypes, HIV/HCV co-infection and those who have received a liver transplant.  While significant progress has been made in the treat of HCV, many clinicians with HCV-infected patients are not aware of the full range of complex and emerging management and treatment options avaialable or how to best apply them to various patient scenarios.

This three-part online program entitled, "The Changing Landscape of HCV Treatment: Assessing All the Options," includes: (1) four thought leader interview featuring a variety of backgrounds and practice approaches in HCV management and treatment; (2) two case-based panel discussions that review and discuss current cilinical data and practice strategies in HCV treatment; (3) ten video presentations, each covering a critical phase of HCV management and treatment.  The different sections of this program bring together some of the leading experts on HCV patient management and will offer viewers current, useful and important clinical information on screening, diagnosing, treating and managing various HCV patient types.  Participants who complete this program will develop knowledge and skills needed to reduce morbidity and mortality among the HCV patient population.

Back to Top

Course Directors:

Douglas T. Dieterich, MD
Professor of Medicine and Director of CME,
Department of Medicine
Director of Outpatient Hepatology
Division of Liver Diseases
Mount Sinai School of Medicine
New York, New York
Paul Kwo, MD
Professor of Medicine
Medical Director, Liver Transplantation
Division of Gastroenterology and Hepatology
Indiana University School of Medicine
Indianapolis, Indiana
Back to Top

Program Faculty:

Brenda Appolo PA-C, MHS
Hepatology Physician Assistant
Physician Assistant /
Nurse Practitioner Manager
Division of Gastroenterology
University of Pennsylvania
Philadelphia, Pennsylvania
Nezam H. Afdhal, MD
Professor of Medicine,
Harvard School of Medicine
Chief of Hepatology,
Director of Liver Center
Beth Israel Deaconess
Medical Center
Boston, Massachusetts,
David E. Bernstein, MD, FACG
Chief Division of Hepatology and
Center for Liver Diseases
North Shore Long Island
Jewish Health Care System
Professor of Medicine
Hofstra North Shore-LIJ
School of Medicine
New York, New York
Ian Frank, MD
Professor of Medicine
Director, Clinical Therapeutics Program
Penn Center for AIDS Research
Perelman School of Medicine at the University of Pennsylvania
Philadelphia, Pennsylvania
Lennox Jeffers, MD
Chief of Hepatology
Miami VA Medical Center
Associate Chief
Center for Liver Disease,
Professor of Medicine
University of Miami’s
School of Medicine
Miami, Florida
Wilbert Jordan, MD
Medical Director
Charles Drew Medical Center
Los Angeles, California
Alain H. Litwin, MD, MPH
Professor of Medicine
Professor of Clinical Psychiatry
& Behavioral Sciences
Albert Einstein College of Medicine
Montefior Medical Center
Bronx, New York
Mark Sulkowski, MD
Professor of Medicine and
Medical Director
Viral Hepatitis Center
Johns Hopkins University
School of Medicine
Baltimore, Maryland
Stacey B. Trooskin, MD, PhD
Assistant Professor
Division of Infectious Diseases
and HIV Medicine
Drexel University College of Medicine
Philadelphia, Pennsylvania
Back to Top

Learning Objectives:

After completing this activity, the participant should be better able to:

  • Explain and implement national guidelines for testing and diagnosing people with CHC
  • Develop the skills to link diagnosed patients with HCV infection to appropriate and effective care
  • Utilize current standards and guidelines for the individualized and optimal management of a variety of patients with CHC, including patients with cirrhosis, renal disease, prior treatment, liver transplant, and HIV/HCV co-infection
  • Discuss recent reports and studies on HCV treatments and strategies and describe how these will impact their practice.

Release Date: May 20, 2016

Expiration Date: May 20, 2017

Estimated time to complete each Module: 

  • Thought Leader Interviews: 30-45 minutes
  • Case-based Panel Discussions:1 hour, 15 minutes
  • Clinical Practice Videos: 30 minutes

Media: Internet

Back to Top

Target Audience:

This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HCV infection.

Back to Top

Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and ViralEd, Inc. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Back to Top

Credit Designation:

Thought Leader Interviews:

Interview 1 (VA Perspective):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interview 2 (Managed Care Perspective):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Interview 3 (HIV/HCV Co-infection Perspective):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Interview 4 (Academic Perspective):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 


Case-Based Panel Discussions:

Panel Discussion led by Paul Kwo, MD:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Panel Discussion led by Douglas Dieterich, MD:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Clincial Practice Videos:

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. There will be 10 instructional videos available for a total of 4.50 possible credit hours.

Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Back to Top

Disclosure of Conflicts of Interest:

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Brenda Appolo PA-C, MHS
  • Consulting Fees: BMS, Merck, Gilead
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g., speakers' bureaus: BMS, Merck, Gilead
Nezam Afdhal, MD
  • Consulting Fees: Merck, Gilead, Echosens, GSK, Ligand, Janssen, Roivant, Co-Crystal, Shionogi
  • Research Support: Gilead, Abbvie, BMS
  • Employee/Salary: Spring Bank Pharmaceuticals
  • Other: Director-TRIO Healthcare
  • Stock: Allurion, Gilead, Spring Bank Pharmaceuticals
David E. Bernstein, MD, FACG
  • Consulting Fees: Abbvie, Gilead, Merck
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g., speakers' bureaus: Abbvie, BMS, Gilead, Merck
  • Contracted Research: Abbvie, BMS, Gilead, Merck
Douglas Dieterich, MD
  • Consulting Fees: Gilead, BMS, AbbVie, Janssen
  • Fees for Non-CME/CE Services Received Directly from a Commercial Interest or thier Agents (e.g., speakers' bureaus: Gilead, BMS, AbbVie, Janssen
  • Contracted Research: Gilead, BMS, AbbVie, Janssen
Ian Frank, MD
  • Consulting Fees: Gilead, BMS
  • Contracted Research (to UPenn): ViiV, GSK
Paul Kwo, MD
  • Consulting Fees: Abbott, Abbvie, Quest, CVS, BMS, Gilead, Janssen, Merck, Alnylam
  • Contracted Research: Abbvie, BMS, Gilead, Janssen, Merck, Contanus
  • Other (DSMB): Inovio
Lennox Jeffers, MD
  • Nothing to Disclose
Wilbert Jordan, MD
  • Contracted Research: Gilead
Alain H. Litwin, MD, MPH
  • Consulting Fees: Gilead, Merck, Abbvie, BMS, Janssen
  • Contracted Research: Gilead, Merck
Mark Sulkowski, MD
  • Contracted Research (to JHU): Abbvie, Gilead, Janssen, Merck
  • Consulting Fees: Abbvie, Co-Crystal, Gilead, Janssen, Merck, Trek
Stacey B. Trooskin, MD, PhD
  • Consulting Fees: Gilead
  • Contracted Research: Gilead

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The following PIM planners and managers, Judi Smelker-Mitchek, RN, BSN, Trace Hutchison, PharmD, Samantha Mattucci, PharmD, CHCP and Jan Schultz, MSN, RN, CHCP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Back to Top

Instructions for Participation and Credit

Thought Leader Interviews

There are no fees for participating and receiving CME credit for this activity. During the period, May 20, 2016 through May 20, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11607. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Case-Based Panel Discussions

There are no fees for participating and receiving CME credit for this activity. During the period, May 27, 2016 through May 27, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11608. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Clinical Practice Videos

There are no fees for participating and receiving CME credit for this activity. During the period, June 2, 2016 through June 2, 2017, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to received acknowledgment of completing this activity, please complete the post-test and evaluation on http://www.cmeuniversity.com/. On the navigation menu, click on "Find Post-test/Evaluation by Course" and search by course ID 11609. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

 

Back to Top

Disclosure of Unlabeled Use:

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Back to Top

Disclaimer:

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Back to Top

PIM-LOGO

ViralEd Logo 

 

 This activity is supported by an unrestricted educational grant from Merck & Co., Inc.


Prepare to print

Share this page:

Get link code to this page                     


Back to Top